The CYE Conference 2012 will be held in Helsinki, Finland.

Starting on Friday the 7th September going through to the 9th.

On Thursday the 6th a Coeliac Youth Work Training will be held.

During the training there will be speakers that will teach you how to start up a Coeliac Youth Group in your country.

Hope to see you there!

Hello everyone,
thanks to the help of those sending us texts we will be able to have the first issue of the CYE Bulletin, which will be spread out in February!
The name of our bulletin will be "Beat the Wheat"
We want to inform you that the name competition we launched in November has been won by Christia Simillidou from Cyprus: she will be awarded by a special prize (you will know more about it in the first issue).
You can already subscribe to "Beat the Wheat" through our website (here to the left!!!)
Best wishes for 2012,
on behalf of CYE Board and the Editorial Board

Francesco Valitutti
CYE Project Manager

The information package for next year's summer camp is finally here!

Read all about it here!

The link to the registration form will be published on CYE website and facebook when

registration starts Feburary 1 st (the registration will go through NCFU's website)

Also when registering for the camp you will need to send a copy of an official ID to  This e-mail address is being protected from spambots. You need JavaScript enabled to view it

within 12th of Febuary in order for the registration to be valid.

“These results are important as they demonstrate for the first time, in a controlled clinical trial, that a drug has the potential to diminish gluten-induced injury in celiac disease patients” said Markku Mäki, Director of Celiac Disease Research Group, Professor at the University of Tampere.

41 well-controlled celiac disease patients who were maintained on a gluten-free diet for one or more years participated in the trial. Half of study patients received ALV003 as study drug and the other half received placebo for six weeks at the time of ingestion of 2g of daily gluten (equivalent to approximately one-half of a slice of bread). Study participants underwent small bowel biopsy at the beginning of the trial and at the end of the trial. The primary endpoint was intestinal mucosal changes caused by gluten, which were evaluated from the biopsy samples taken.

In this clinical trial it was shown that ALV003 diminished gluten-induced intestinal mucosal injury in celiac disease. Biopsy results showed that after six weeks exposure to gluten, there was significantly less small intestinal mucosal injury in patients given with ALV003 than in placebo-treated patients. In addition, the data showed significant differences in changes in IEL between the study groups.

The results were announced at the United European Gastroenterolgy Week (UEGW) scientific meeting in Stockholm. Based on the positive results, the next phase of the clinical trial is targeted to start in 2012.

Read more from Finnmedi website